Sample size correction for treatment crossovers in randomized clinical trials with a survival endpoint

Controlled Clinical Trials

Volumn 23, Issue 6, 2002, Pages 650-661

  Porcher, Raphaël ^a,b   Lévy, Vincent ^a,b   Chevret, Sylvie ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Crossover; Gehan Wilcoxon statistic; Log rank statistic; Randomized clinical trials; Sample size

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; HYPOTHESIS; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SIMULATION; STATISTICAL ANALYSIS; SURVIVAL;

CROSS-OVER STUDIES; HUMANS; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIALS; RISK; SAMPLE SIZE; STATISTICS, NONPARAMETRIC; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS;

EID: 0036911409     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(02)00239-8     Document Type: Article

References (19)

1. Senn S. Statistical issues in drug development. 1997;John Wiley & Sons, Chichester.
2. Neyman J., Pearson E.S. On the use and interpretation of certain test criteria for purpose of statistical inference. Part I and II. Biometrika. 20:1928;175-240., 263-294.
3. Freedman L.S. Tables of the number of patients required in clinical trials using the logrank test. Stat Med. 1:1982;121-129.
4. Yusuf S., Collins R., Peto R. Why do we need some large, simple randomized trials? Stat Med. 3:1984;409-422.
5. DeMets D.L., Pocock S.J., Julian D.G. The agonising negative trend in monitoring of clinical trials. Lancet. 354:1999;1983-1988.
6. Lakatos E. Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics. 44:1988;229-241.
7. Lakatos E. Sample size determination in clinical trials with time-dependent rates of losses and noncompliance. Control Clin Trials. 7:1986;189-199.
8. Shih J.H. Sample size calculation for complex clinical trials with survival endpoints. Control Clin Trials. 16:1995;395-407.
9. Schoenfeld D. The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika. 68:1981;316-318.
10. Gehan E.A. A generalized Wilcoxon test for comparing arbitrarily single-censored samples. Biometrika. 52:1965;203-223.
11. Tarone R.E., Ware J. On distribution-free tests of equality of survival distributions. Biometrika. 64:1977;156-160.
12. Fermand J.P., Ravaud P., Chevret S.et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma. up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial Blood. 92:1998;3131-3136.
13. Fayers P.M., Cuschieri A., Fielding J.et al. Sample size calculation for clinical trials. the impact of clinician beliefs Br J Cancer. 82:2000;213-219.
14. Machin D., Campbell M.J. Statistical tables for the design of clinical trials. 1987;Blackwell Scientific Publications, Oxford.
15. George S.L., Desu M.M. Planning the size and duration of a clinical trial studying the time to some critical event. J Chronic Dis. 27:1974;15-24.
16. Rubinstein L.V., Gail M.H., Santner T.J. Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. J Chronic Dis. 34:1981;469-479.
17. Lachin J.M., Foulkes M.A. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics. 42:1986;507-519.
18. Freedman L.S. The effect of partial noncompliance on the power of a clinical trial. Control Clin Trials. 11:1990;157-168.
19. Lakatos E., Lan K.K.G. A comparison of sample size methods of the logrank statistics. Stat Med. 11:1992;179-191.